PALMITAMIDE MEA

Palmitamide MEA is a fatty acid amide produced in the body that binds to and activates the peroxisome proliferator-activated receptor alpha (PPAR-α). 
Palmitamide MEA was initially described as an agonist to the type 2 cannabinoid receptor (CB2), though it is now recognized that PEA does not bind to cannabinoid receptors. 
Palmitamide MEA is known to have anti-inflammatory, analgesic, and neuroprotective properties. 

CAS Number: 544-31-0
Molecular Formula: C18H37NO2
Molecular Weight: 299.49
EINECS Number: 208-867-9

Synonyms: Formic acid, sodium salt, Formic acid, sodium salt (1:1), Salachlor, Mravencan sodny, FORMIC ACID, NA SALT, Sodium formate, refined, Formic acid sodium salt (1:1), 387AD98770, DTXSID2027090, CHEBI:62965, NSC-77457, RefChem:183890, DTXCID407090, 205-488-0, 690-860-9, Formic acid sodium salt, sodium;formate, CHNaO2, MFCD00013101, sodium formiate, sodiumformate, Mravencan sodny [Czech], Formic Acid Sodium Salt; NA-Amasil, CHEMBL183491, CCRIS 1037, HSDB 744, E237, EINECS 205-488-0, NSC 77457, sodium carbanate, 84050-17-9, Sodium methanoate, UNII-387AD98770, HCOONa, HCO2Na, Sodium formate, ACS grade, EC 205-488-0, SCHEMBL2354, SODIUM FORMATE [MI], SODIUM FORMATE [HSDB], orb2946012, SCHEMBL4270656, SODIUM FORMATE [WHO-DD], MSK001902, AKOS015902050, AKOS015960483, FF37012, HY-W088065, MSK001902-1000W, BP-14115, FORMIC ACID, SODIUM SALT, [14C], DB-210177, NS00079373, N-(2-HYDROXYETHYL)HEXADECANAMIDE;N-HEXADECANOYLETHANOLAMINE;PEA PALMIDROL;PALMITYLETHANOLAMIDE;PALMITOYLETHANOLAMIDE;PALMITOYLETHANOLAMIDE N-(2-HYDROXYETHYL)HEXADECANAMIDE;n-(2-hydroxyethyl)-hexadecanamid;Palmidrol, Palmitoylethanolamide, Palmidrol, 544-31-0, N-(2-Hydroxyethyl)hexadecanamide, Palmitoyl ethanolamide, Palmitic acid monoethanolamide, Hydroxyethylpalmitamide, Loramine P 256, palmitylethanolamide, Palmidrolum, Levagen, Palmdrol prodes, Anandamide (16:0), Monoethanolamine palmitic acid amide, palmitic monoethanolamide, Palmitinsaeure-beta-hydroxyethylamid, hexadecanoyl ethanolamide, N(2-hydroxyethyl)palmitide, 6R8T1UDM3V, N(2-hydroxyethyl) palmitide, NSC-23320, N-(2-hydroxyethyl)-palmitide, FSD-201, n-palmitoyl ethanolamide, AM 3112, CHEBI:71464, NSC23320, SCI-110 component palmitoylethanolamide, n-palmitoylethanolamide, N-(2-hydroxyethyl)palmitate, OptiPEA, RefChem:858399, 208-867-9, Palmitamide MEA, Impulsin, N-(2-Hydroxyethyl)palmitamide, N-palmitoylethanolamine, Palmitoyl-EA, HEXADECANAMIDE, N-(2-HYDROXYETHYL)-, Palmidrol [INN], MFCD00020562, C18H37NO2, N-hexadecanoylethanolamine, NSC 23320, PEA (Chemical), N-palmitoyl ethanolamine, N-hexadecanoyl-ethanolamine, DTXSID4042254, Palmidrol (INN), Palmitoylethanolamid?e, NCGC00015793-03, AM 3112;Loramine P 256;Mackpeart DR 14V, DTXCID2022254, Palmidrolum [INN-Latin], CAS-544-31-0, 2-Palmitoylaminoethanol, SR-01000076055, EINECS 208-867-9, UNII-6R8T1UDM3V, MimyX, Anandamide C16:0, Tocris-0879, N-hexadecyl-ethanolamine, PALMIDROL [MI], Lopac-P-0359, PALMIDROL [MART.], Palmityoletanolamide (PEA), 2-PALMITAMIDOETHANOL, PALMIDROL [WHO-DD], CBiol_002043, Lopac0_000905, BSPBio_001454, KBioGR_000174, KBioSS_000174, MLS002153421, SCHEMBL120518, BML2-B10, CHEMBL417675, GTPL3622, orb1300340, Palmidrol|N-palmitoylethanolamine, BDBM29083, KBio2_000174, KBio2_002742, KBio2_005310, KBio3_000347, KBio3_000348, Bio1_000329, Bio1_000818, Bio1_001307, Bio2_000174, Bio2_000654, HMS1361I16, HMS1791I16, HMS1989I16, HMS2234L19, HMS3264C10, HMS3266N08, HMS3374K03, HMS3402I16, HMS3411B14, HMS3649L03, HMS3675B14, N-(2-hydroxyethyl) hexadecanamide, Pharmakon1600-01506156, CS-D1253, NAE 16:0, Tox21_110222, ANA(16:0), LMFA08040013, NAE(16:0), NSC760371, s4708, STL454872, AKOS002676363, Tox21_110222_1, CCG-204987, DB14043, FP76687, LP00905, NSC-760371, SDCCGSBI-0050880.P002, IDI1_033924, s10398, NCGC00015793-01, NCGC00015793-02, NCGC00015793-04, NCGC00015793-05, NCGC00015793-06, NCGC00015793-07, NCGC00015793-08, NCGC00015793-09, NCGC00015793-10, NCGC00015793-12, NCGC00024840-01, NCGC00024840-02, NCGC00024840-05, NCGC00024840-06, NCGC00024840-07, NCGC00024840-08, NCGC00024840-09, AS-14094, HY-20685, PALMITOYLETHANOLAMIDE [NFLIS-DRUG], SMR000058371, SY211643, Hexadecanoic acid (2-hydroxy-ethyl)-amide, EU-0100905, NS00013930, P2670, D08328, EN300-311967, N-(2-Hydroxyethyl)hexadecanamide;Palmidrol;PEA, P 0359, AB00918319_06, F530116, Q2159860, SR-01000076055-1, SR-01000076055-3, SR-01000076055-7, BRD-K68095457-001-04-4, BRD-K68095457-001-10-1, BRD-K68095457-001-11-9, Z2242151306

Palmitamide MEA supplements have been used by people with chronic pain as well as those with neuropathic pain.
Palmitamide MEA is a naturally occurring fatty acid amide composed of palmitic acid and ethanolamine that forms part of the body’s endogenous lipid-signaling system.
Palmitamide MEA belongs to the N-acylethanolamine family and acts as an autacoid molecule involved in regulating inflammation, pain, and cellular homeostasis.

Because of these biochemical properties, it is widely used as a bioactive compound in nutraceutical, pharmaceutical, and biomedical applications.
Palmitamide MEA is known for its ability to modulate mast cell activity and inflammatory signaling pathways through mechanisms such as ALIA (Autacoid Local Injury Antagonism).
This modulation helps reduce excessive immune responses and contributes to its analgesic and anti-inflammatory effects.

These biological actions make it an important compound for managing chronic discomfort, neuroinflammation, and tissue stress.
The compound functions as a peroxisome proliferator-activated receptor-alpha (PPAR-α) agonist, which allows it to influence gene expression related to inflammation and cellular repair.
Through this receptor interaction, it promotes neuroprotective effects and supports healthy cellular metabolism.

This receptor-based activity explains its use in neurological, musculoskeletal, and systemic inflammation contexts.
Palmitamide MEA is found naturally in foods such as egg yolks, peanuts, and soybeans, as well as being produced by human tissues under stress.
Its endogenous presence highlights its physiological importance as a self-regulating protective molecule.

This makes supplemental forms attractive for supporting the body’s natural defense processes.
Palmitamide MEA is typically provided in purified or micronized formulations to enhance absorption and biological activity.
Micronization increases surface area and improves bioavailability, leading to more effective physiological responses.

These engineered forms are used in therapeutic products designed to support pain reduction and inflammatory balance.
Palmitamide MEA is a natural occurring lipid belonging to the class of autacoids. 
It is a fine white to yellow powder. 

Palmitamide MEA consists of palmitic acid and ethanolamine. 
It is the hydrolyzed form of N-(2-hydroxyethyl)-palmitamide, a crystalline structure isolated in soy lecithin. 
Palmitamide MEA is this hydrolyzed substance that accounts for the anti-inflammatory properties that were first noted by scientists in 1957. 

Palmitamide MEA's effects on the immune system have been studied since 1939.
Palmitamide MEA is an N-(long-chain-acyl)ethanolamine that is the ethanolamide of palmitic (hexadecanoic) acid. 
It has a role as an anti-inflammatory drug, an antihypertensive agent, a neuroprotective agent and an anticonvulsant. 

Palmitamide MEA is a N-(long-chain-acyl)ethanolamine, an endocannabinoid and a N-(saturated fatty acyl)ethanolamine. 
It is functionally related to a hexadecanoic acid.
Palmitamide MEA is a modern cosmetic ingredient known for its skin-conditioning properties. 

Palmitamide MEA is often used as a moisturizer and skin barrier-strengthening component, helping to retain moisture and giving the skin a soft feel. 
Palmitamide MEA is of synthetic origin, created in laboratories to meet the high standards of the cosmetics industry. 
Its chemical structure is based on the palmitamide family, with palmitic acid as the main component.

Palmitamide MEA is used in various products, such as creams, lotions, and serums, to improve skin texture and appearance. 
This ingredient is becoming increasingly popular due to its effectiveness and ability to adapt to various skin types.

Melting point: 97–98 °C
Boiling point: 461.5 ± 28.0 °C (Predicted)
Density: 0.910 ± 0.06 g/cm³ (Predicted)
Vapor pressure: 0.45 Pa at 20 °C
RTECS: ML8950000
Storage temp.: –20 °C
Solubility: Soluble in DMSO (up to 25 mg/mL) or ethanol (up to 25 mg/mL)
Form: White solid
pKa: 14.49 ± 0.10 (Predicted)
Color: White
Water solubility: 4.01 mg/L at 20 °C
Stability: Stable for 2 years as supplied; solutions in DMSO/ethanol stable at –20 °C for up to 3 months
InChIKey: HXYVTAGFYLMHSO-UHFFFAOYSA-N
LogP: 3.989 at 20 °C

Palmitamide MEA is a fatty acid amide molecule involved in a variety of cellular functions in chronic pain and inflammation. 
Palmitamide MEA has been shown to have neuroprotective, anti-inflammatory, anti-nociceptive (antipain) and anti-convulsant properties. 
Often in people with chronic disorders, the body does not produce enough PEA, which causes problems.

Taking Palmitamide MEA to supplement the body’s shortage is may be beneficial if you have chronic and neuropathic pain and inflammation, as has been demonstrated in clinical trials.
These include peripheral neuropathies such as diabetic neuropathy, chemotherapy-induced peripheral neuropathy, carpal tunnel syndrome, sciatic pain, osteoarthritis, low-back pain, failed back surgery syndrome, dental pains, neuropathic pain in stroke and multiple sclerosis, chronic regional pain syndrome, chronic pelvic pain, postherpetic neuralgia, and vaginal pains.

Palmitamide MEA is a novel tropical whiteweed/billy goatweed (Ageratum conyzoides) aerial extract that has been traditionally used in the Caribbean to support prostate health. 
Palmitamide MEA is the culmination Gencor’s efforts to develop of a proprietary extraction process using ethanol and water. 
First developed as an extract for prostate health, Gencor recognized the ingredient’s mechanism of action (MOA) also lent itself being an ideal ingredient for hair health.

Palmitoylethanolamide (PEA) is a natural fatty acid amide of ethanolamine and palmitic acid. 
It is found in soybeans, egg yolk, and many other food sources. 
Palmitamide MEA is an endogenous cannabinoid receptor agonist. 

It is a peroxisome proliferator-activated receptor α (PPAR-α) ligand. 
Palmitamide MEA possesses anti-inflammatory, anti-allergic, neuroprotective, and analgesic activities. 
It belongs to the class of lipid mediators and the N-acylethanolamine family. 

Palmitamide MEA blocks the release of pro-inflammatory mediators from activated mast cells and prevents the recruitment of activated mast cells at the site of nerve injury.
There are no known problematic side-effects. 
Palmitamide MEA can be taken together with any other substance. 

It enhances the pain-relieving effect of classic analgesics and anti-inflammatories. 
Palmitamide MEA can be used in combination with other substances without any side effects.
Palmitamide MEA is used as a pearlized agent for rinse formulations. 

Palmitamide MEA is also suitable for formulations for sensitive skin because of its anti-inflammatory effect. 
Palmitamide MEA is an endogenous fatty-acid amide formed naturally in the human body and many animal tissues as part of the body’s protective and anti-inflammatory response system.
It consists of palmitic acid linked to ethanolamine, creating a bioactive lipid molecule capable of interacting with cellular receptors that regulate inflammation and pain.

Because of these biological functions, it is widely recognized as a modulator of neuroinflammation and chronic pain signaling pathways.
Palmitamide MEA is chemically classified as N-(2-hydroxyethyl)hexadecanamide and belongs to the family of N-acylethanolamines that play key roles in maintaining cellular homeostasis.
Its molecular structure allows it to integrate into cell membranes and influence multiple biochemical cascades related to immune function, mast-cell activity, and inflammatory mediator release.

This ability makes it valuable in therapeutic applications targeting chronic inflammation, nerve discomfort, and tissue stress responses.
Palmitamide MEA is widely used as a nutraceutical ingredient because of its known ability to support natural anti-inflammatory processes without acting like traditional pharmaceuticals.
It does not directly bind to classical cannabinoid receptors but instead acts through alternative pathways such as PPAR-α activation and mast-cell downregulation.

These mechanisms allow it to reduce overactive inflammatory responses while maintaining a high level of biological safety.
Palmitamide MEA is also valued for its neuroprotective potential, as it helps stabilize overactive neural pathways associated with neuropathic pain and sensory hypersensitivity.
Its lipid-based nature allows it to cross biological barriers and reach nerve tissues where it modulates excessive inflammatory signaling.

This makes it relevant in formulations aimed at nerve discomfort, muscle tension, and chronic pain management.
Palmitamide MEA is frequently incorporated into dietary supplements, topical formulations, and medical nutrition products designed to reduce localized or systemic inflammation.

Its high tolerability allows it to be used long term, making it attractive for populations needing continuous symptom management.
For this reason, it is commonly marketed under trade names such as OptiPEA, Palmidrol, and Levagen.

Uses Of Palmitamide MEA:
Palmitamide MEA is a natural substance produced by the body and it is very effective and safe to use as a supplement for pain and reduce inflammation.
Palmitamide MEA can be synthesized within the human body from the abundant fatty acid palmitic acid, but it is not dependent or influenced by dietary consumption of fatty acids. 
Palmitamide MEA in the diet is derived from dairy products such as cheese and butter, palm tree oil, and animal meat products. 

However, increasing palmitic acid in the hope of increasing endogenous Palmitamide MEA synthesis will not be effective.
The anti-inflammatory properties of PEA are due to its ability to inhibit inflammation-causing proteins called cytokines. 
Cytokines are released during periods of inflammation. 

Palmitamide MEA can suppress the secretion of tumor necrosis factor alpha (TNF alpha), a cytokine, while also inhibiting the release of interleukins. 
Interleukins are a specific class of cytokines which belong in the immunological system and are activated during the process of inflammation.
Palmitamide MEA is widely used as a bioactive lipid compound to support the body’s natural anti-inflammatory mechanisms, especially in tissues that experience chronic irritation or cellular stress.

Its activity helps stabilize mast cells and reduce the release of pro-inflammatory mediators, which contributes to decreased discomfort and improved tissue resilience.
This makes it a popular ingredient in supplements and formulations targeting long-term inflammatory balance.
The compound is used in nutraceuticals that aim to reduce neuropathic discomfort by modulating the endocannabinoid-related signaling pathways in nerve cells.

Its presence supports healthier nerve function by influencing cellular responses without producing psychoactive effects.
These properties allow it to be included in formulations meant for nerve wellness and daily comfort management.
Palmitamide MEA is used in topical creams and gels where it provides localized relief by interacting with skin receptors involved in inflammation and sensitivity.

The topical film formed after application delivers slow, steady exposure to the skin, helping improve comfort in targeted areas.
Such formulations are often used in joint creams, muscle gels, and dermal soothing products.
The compound is incorporated into veterinary formulations because animals also benefit from its natural ability to regulate inflammatory responses.

Its safety profile allows it to be added to pet supplements, chews, and topical balms intended for joint support and general comfort.
This makes it valuable in maintaining mobility and well-being in older or active animals.
Palmitamide MEA is used in research settings as a model compound to study lipid mediators and their role in cellular stress responses.

Its predictable biological activity allows researchers to evaluate how endogenous fatty acid amides influence inflammation, neuroprotection, and immune modulation.
These studies contribute to the development of new therapeutic approaches involving fatty acid amide pathways.
Palmitamide MEA is also used in formulations that aim to support sleep quality and relaxation due to its stabilizing effects on cellular pathways involved in nighttime regulation.

Its calming influence on overactive inflammatory signaling may indirectly support better rest and recovery.
For this reason, it appears in some relaxation and recovery supplements as a non-sedative supportive ingredient.

Palmitamide MEA is included in skin-care products where it helps calm irritated skin and support the skin barrier against environmental stress.
Its lipid-based structure allows it to blend well with moisturizers, serums, and barrier-repair creams.
These benefits make it ideal for sensitive-skin formulations and recovery-focused cosmetic products.

Safety Profile Of Palmitamide MEA:
Palmitamide MEA is a fatty acid ethanolamide naturally derived from palmitic acid and monoethanolamine, forming a bioactive lipid involved in cellular signaling and anti-inflammatory regulation.
It belongs to the family of endogenous compounds called N-acylethanolamines, which play important roles in pain modulation, inflammation control, and neuroprotection.
Because of these biological functions, Palmitamide MEA is widely used as a nutraceutical ingredient, research chemical, and therapeutic support compound.

Palmitamide MEA forms a waxy, lipid-like solid that dissolves slowly in biological membranes due to its long hydrophobic chain and polar ethanolamide group.
This amphiphilic structure allows it to interact with cell receptors and lipid layers, influencing inflammatory pathways and mast cell activity.
Its biochemical profile makes it compatible with dietary supplements, topical formulations, and experimental pharmaceutical products.

Palmitamide MEA is known for supporting the endocannabinoid system indirectly, even though it does not bind strongly to classical cannabinoid receptors.
Instead, it modulates enzymes and nuclear receptors such as PPAR-alpha, leading to reduced inflammatory signaling and improved cellular homeostasis.
This mechanism is why it is used in wellness applications targeting chronic inflammation, neuropathic discomfort, and stress-related biological imbalance.

Palmitamide MEA is highly stable under normal storage conditions because of its saturated fatty acid backbone, which resists oxidation.
Its chemical stability makes it suitable for solid capsules, lipid-based formulations, and long-term product storage without rapid degradation.
This stability contributes to its increasing popularity in nutraceutical and specialized medical nutrition fields.